Published in Cancer Inform on July 24, 2012
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res (2014) 2.18
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol (2014) 1.74
Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res (2013) 1.23
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res (2014) 1.19
Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence. J Clin Oncol (2015) 1.06
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res (2014) 1.05
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One (2016) 1.03
Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res (2014) 1.02
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res (2015) 0.98
Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer. Am J Cancer Res (2013) 0.90
Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ. Expert Rev Mol Diagn (2013) 0.88
RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res (2016) 0.87
Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med (2015) 0.85
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer. Breast Cancer Res (2016) 0.83
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Res Treat (2014) 0.80
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res (2016) 0.80
Genomic profiling of breast cancers. Curr Opin Obstet Gynecol (2015) 0.80
Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging. Breast Cancer Res Treat (2015) 0.80
DupChecker: a bioconductor package for checking high-throughput genomic data redundancy in meta-analysis. BMC Bioinformatics (2014) 0.79
Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. Breast Cancer Res (2015) 0.78
Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers. Oncotarget (2016) 0.78
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. Int J Mol Sci (2017) 0.78
Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers. PLoS One (2016) 0.77
Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis. PLoS One (2015) 0.77
A single-nucleotide polymorphism in the 3'-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer. Oncotarget (2016) 0.77
Of Mice and Women: A Comparative Tissue Biology Perspective of Breast Stem Cells and Differentiation. J Mammary Gland Biol Neoplasia (2015) 0.77
RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining. Int J Genomics (2016) 0.77
The geographic distribution of mammography resources in Mississippi. Online J Public Health Inform (2014) 0.77
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (2017) 0.76
Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis. Oncoimmunology (2015) 0.76
Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. Mol Cancer Ther (2014) 0.76
Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women. Ann Surg Oncol (2015) 0.76
Molecular Classification of Triple-Negative Breast Cancer. J Breast Cancer (2016) 0.76
The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. Clin Cancer Res (2016) 0.75
Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer. J Nat Prod (2016) 0.75
Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer (2017) 0.75
A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC). Clin Cancer Res (2017) 0.75
Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. NPJ Breast Cancer (2017) 0.75
Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. J Cancer Res Clin Oncol (2016) 0.75
Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Front Oncol (2017) 0.75
Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. Nat Commun (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Triple-negative breast cancer. N Engl J Med (2010) 11.39
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol (2006) 6.07
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol (2005) 5.63
Triple negative tumours: a critical review. Histopathology (2008) 4.94
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol (2010) 2.23
Statistical process control for large scale microarray experiments. Bioinformatics (2002) 1.42
Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat (2009) 1.38
Triple-negative breast cancer. Curr Opin Oncol (2008) 1.07
Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status. PLoS One (2010) 0.97
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet (2003) 4.01
The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell (2012) 3.91
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol (2003) 3.00
Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res (2003) 2.70
The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med (2007) 2.62
Nrf2, a multi-organ protector? FASEB J (2005) 2.61
Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int (2004) 2.52
The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal (2009) 2.49
Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res (2004) 2.33
A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem (2007) 2.32
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol (2008) 2.10
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res (2005) 2.06
Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.05
The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis (2004) 1.87
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res (2006) 1.85
Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res (2006) 1.84
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog (2010) 1.81
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov (2011) 1.76
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol (2014) 1.74
p63: Molecular complexity in development and cancer. Carcinogenesis (2004) 1.69
Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem Res Toxicol (2006) 1.69
Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res (2013) 1.66
Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int (2004) 1.66
New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res (2014) 1.65
Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol (2011) 1.63
Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J Natl Cancer Inst (2002) 1.63
Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Biomed Res Int (2013) 1.61
The DNA binding activity of p53 displays reaction-diffusion kinetics. Biophys J (2006) 1.61
Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res (2005) 1.61
Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data. PLoS One (2013) 1.61
Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J (2005) 1.61
DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest (2014) 1.59
In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res (2004) 1.55
Ultrafast dynamics and anionic active states of the flavin cofactor in cryptochrome and photolyase. J Am Chem Soc (2008) 1.55
Evidence Combination From an Evolutionary Game Theory Perspective. IEEE Trans Cybern (2015) 1.54
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov (2013) 1.54
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res (2011) 1.53
Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. J Natl Cancer Inst (2010) 1.51
Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun (2005) 1.50
Monster cells in malignant melanoma. Am J Dermatopathol (2005) 1.49
Alcohol drinking, cigarette smoking, and risk of colorectal adenomatous and hyperplastic polyps. Am J Epidemiol (2008) 1.47
Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol (2003) 1.46
Dynamics and mechanism of cyclobutane pyrimidine dimer repair by DNA photolyase. Proc Natl Acad Sci U S A (2011) 1.45
Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol (2005) 1.44
Steps to ensure accuracy in genotype and SNP calling from Illumina sequencing data. BMC Genomics (2012) 1.44
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res (2010) 1.43
Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res (2010) 1.43
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42
Quantitative metrics in clinical radiology reporting: a snapshot perspective from a single mixed academic-community practice. Magn Reson Imaging (2012) 1.42
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol (2007) 1.40
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med (2004) 1.40
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
Functional genomic screens identify CINP as a genome maintenance protein. Proc Natl Acad Sci U S A (2009) 1.38
Finding the lost treasures in exome sequencing data. Trends Genet (2013) 1.36
The role of van der Waals forces in the performance of molecular diodes. Nat Nanotechnol (2013) 1.36
A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res (2003) 1.36
Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. EMBO Rep (2010) 1.36
Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin Cancer Res (2006) 1.34
A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol (2008) 1.34
The effect of strand bias in Illumina short-read sequencing data. BMC Genomics (2012) 1.34
Gene expression in human neural stem cells: effects of leukemia inhibitory factor. J Neurochem (2003) 1.34
Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther (2007) 1.33
IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res (2005) 1.33
A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis (2012) 1.32
Proteomic patterns of preinvasive bronchial lesions. Am J Respir Crit Care Med (2005) 1.32
Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci (2003) 1.32
Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res (2003) 1.32
Fish, shellfish, and long-chain n-3 fatty acid consumption and risk of incident type 2 diabetes in middle-aged Chinese men and women. Am J Clin Nutr (2011) 1.32
MitoSeek: extracting mitochondria information and performing high-throughput mitochondria sequencing analysis. Bioinformatics (2013) 1.31
mTOR regulates autophagy-associated genes downstream of p73. Autophagy (2009) 1.31